Osteoinductivity performance dicalcium phosphate dihydrate-coated porous β-tricalcium phosphate granules in adipose-derived mesenchymal stem cells.
Anuar Shariff K., Patera Nugraha A., Hafedh Mohammed Mohammed A., Bagus Narmada I., Gusti Aju Wahju Ardani I., Faradilla Ramadhani N.
Laboratory Study, published in Dent Mater J (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Dent Mater J (2025)
- Country
- Japan
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 40518314
- DOI
- 10.4012/dmj.2024-310
Abstract (original English)
Elucidate the dicalcium phosphate dihydrate (DCPD)-coated-beta-tricalcium phosphate (β-TCP) porous granules osteoinductivity performance in adipose-derived mesenchymal stem cells (ADMSCs). β-TCP porous was made by adding the sodium chloride (NaCl) powders with the dry powder of DCPD and CaCO 3 in the concentrations 40:60 (by wt%). Then, DCPD layer will be formed on porous β-TCP granules by immersing the granules in an acidic calcium phosphate solution. ADMSCs cultured was used to examine the biocompability of 300-600 µm and 600-1,000 µm DCPD-coated-porous β-TCP by means of microculture tetrazolium technique (MTT assay) and scratch assay. Bone morphogenic protein-2 (BMP-2), Osterix, Runt-related transcription factor-2 (Runx2), Alkaline phosphatase (ALP), Osteopontin, Osteonectin expression were investigated. The DCPD-coated porous β-TCP granules were culture together with ADMSCs is biocompatible. BMP-2, Runx2, Osterix, ALP, Osteopontin, Osteonectin expression in ADMSCs after culture together with DCPD-coated-β-TCP significantly enhanced. DCPD-coated-porous-β-TCP granules have good biocompatibility and high osteoconductivity in ADMSCs.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.